- Home
- SLN vs IAUX Comparison
SLN vs IAUX Comparison
Compare SLN & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | IAUX |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLN | IAUX |
|---|---|---|
| Price | $19.78 | $1.40 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | 4.3M | ★ 7.1M |
| Earning Date | 11-24-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | ★ N/A | N/A |
| Revenue | $559,000.00 | ★ $95,193,000.00 |
| Revenue This Year | N/A | $52.32 |
| Revenue Next Year | $131.31 | $67.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 89.12 |
| 52 Week Low | $4.19 | $0.93 |
| 52 Week High | $19.87 | $2.24 |
Technical Indicators
Market Signals| Indicator | SLN | IAUX |
|---|---|---|
| Relative Strength Index (RSI) | 78.28 | 43.30 |
| Support Level | $13.01 | $1.25 |
| Resistance Level | $19.87 | $1.43 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 60.42 | 46.00 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.